Wyeth-Ayerst global pharmaceuticals president will be U.S. pharmaceuticals head Robert Essner.
WYETH-AYERST's ESSNER ASSUMES OPERATING RESPONSIBILITY FOR GLOBAL Rx BUSINESS as president of Wyeth-Ayerst Global Pharmaceuticals. Robert Essner, 49, was previously head of the company's domestic pharmaceutical business as president of Wyeth-Ayerst Laboratories. Essner will report to American Home Products Exec VP Fred Hassan, 51.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth